Trials / NCT03944239
Safety and Efficacy of Subretinal Transplantation of Clinical Human Embryonic Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Retinitis Pigmentosa
Underway, not enrolling Phase 1 Gene therapy, Cell therapy
- Sponsor
- Qi Zhou
- Treatment
- Retinal pigment epitheliums transplantation
- Gene
- Not stated
- Conditions
- Retinitis Pigmentosa
- Ages
- 18 Years to 80 Years
- Enrollment
- 25 participants
- Started
- 2021-05-19
- Main results expected
- 2026-12-31
- Results posted
- Not yet
- Record last updated
- 2026-07-06
What the study is testing
This project intends to transplant a clinical level human embryonic stem cells derived retinal pigment epithelium into subretinal space to treat eetinitis pigmentosa(RP) diseases. Through the statistical analysis EDTRS, BCVA, OCT, ERG, Fluorescein angiography, Ophthalmic AB ultrasound changes between before and after the treatment to assess the efficacy and safety 0f RPE transplants to treat RP disease.
Where it runs
China (1)
- Beijing Tongren Hospitol,Capital Medical University, Beijing, Beijing Municipality